Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets: 2010-2024

Historic Other Non-Current Assets for Ani Pharmaceuticals (ANIP) over the last 12 years, with Dec 2024 value amounting to $12.2 million.

  • Ani Pharmaceuticals' Other Non-Current Assets rose 9.01% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 9.01%. This contributed to the annual value of $12.2 million for FY2024, which is 1.23% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Other Non-Current Assets stood at $12.2 million, which was up 1.23% from $12.1 million recorded in FY2023.
  • Ani Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $12.2 million during FY2024, with a 5-year trough of $5.0 million in FY2021.
  • For the 3-year period, Ani Pharmaceuticals' Other Non-Current Assets averaged around $11.9 million, with its median value being $12.1 million (2023).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first decreased by 0.52% in 2020, then surged by 127.17% in 2022.
  • Ani Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $5.0 million in 2020, then declined by 0.04% to $5.0 million in 2021, then spiked by 127.17% to $11.4 million in 2022, then increased by 6.26% to $12.1 million in 2023, then climbed by 1.23% to $12.2 million in 2024.